Minoryx

Minoryx official website

Total Funding
$106.9M
Last Round
$59.5M Series CMay 2022
Rounds
3

About

Minoryx is a biotechnology company developing treatments for rare central-nervous-system diseases, especially neurodegenerative orphan conditions with substantial unmet need. Its lead program, leriglitazone, is a brain-penetrant selective PPAR gamma agonist in clinical development for multiple CNS disorders, including X-linked adrenoleukodystrophy. The company is headquartered in Mataró, Barcelona, and also maintains an R&D site in Gosselies, Belgium.

Summary

Minoryx is a Biotech company. It has raised $106.9M in total across 3 rounds, most recently a $59.5M Series C round in May 2022. Investors include Ysios Capital, Caixa Capital Risc and Fund+.

Tech & App Stack

1 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Series CSeries CMay 2022
$59.5M

Sign up to see all 3 rounds

Series A through Series C — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Minoryx on Indexed.vc
<a href="https://indexed.vc/companies/minoryx"><img src="https://indexed.vc/api/badge/company/minoryx" alt="Minoryx on Indexed.vc" width="260" height="76" /></a>